META
Meta Platforms, Inc.
META's fundamentals are mixed, but it looks cheap: trading at 21x earnings, below its usual 27x. Analysts expect earnings growth, though they disagree widely on how much.
NAMI
Jinxin Technology Holding Company American Depositary Shares
There isn't enough reported data to score NAMI yet.
META Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
META's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NAMI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NAMI's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
META PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $624 | — |
| Cheap | 21x | $613 | -1.7% |
| Current | 21x | $624 | — |
| Fair | 27x | $803 | +29% |
| Expensive | 32x | $934 | +50% |
Historical ranges are pointers, not guarantees.
META's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
NAMI PE Valuation
NAMI has no meaningful PE right now: it lost money over the past year.
META Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for META, but weaker profitability. However, they disagree widely on these estimates.
NAMI Forward outlook
There aren't enough analyst estimates for NAMI to show an outlook.
META Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $32.16 | +9.7% |
| Q3 2026 | $29.32 | +30% |
| Q2 2026 | $26.54 | -3.7% |
| Q1 2026 | $27.50 | +7.5% |
| Q4 2025 | $23.49 | -1.6% |
| Q3 2025 | $22.58 | +6.5% |
| Q2 2025 | $27.56 | +41% |
| Q1 2025 | $25.58 | +47% |
| Q4 2024 | $23.86 | +60% |
META earned $29.32 per share over the past year, up 30% from the year before.
NAMI Earnings Per Share
NAMI and META do not have enough comparable growth data to identify a winner.
META Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $64.6B | +26% |
| Q2 2026 | $60.8B | +28% |
| Q1 2026 | $56.3B | +33% |
| Q4 2025 | $59.9B | +24% |
| Q3 2025 | $51.2B | +26% |
| Q2 2025 | $47.5B | +22% |
| Q1 2025 | $42.3B | +16% |
| Q4 2024 | $48.4B | +21% |
META has the edge over NAMI in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -20 points |
| Q2 2026 | 31% | -12 points |
| Q1 2026 | 41% | -0.9 points |
| Q4 2025 | 41% | -7 points |
| Q3 2025 | 40% | -2.7 points |
| Q2 2025 | 43% | +5 points |
| Q1 2025 | 41% | +3.6 points |
| Q4 2024 | 48% | +7.4 points |
META has the edge over NAMI on profitability, with a higher operating margin.
NAMI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $21.4M | -32% |
| Q4 2025 | $30.7M | -1.9% |
| Q2 2025 | $31.3M | +5.3% |
| Q4 2024 | $31.3M | -0.7% |
| Q2 2024 | $29.7M | +17% |
META has the edge over NAMI in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -10% | -26 points |
| Q4 2025 | -39% | -60 points |
| Q2 2025 | -11% | -33 points |
| Q4 2024 | -2.3% | N/A |
| Q2 2024 | 16% | N/A |
| Q4 2023 | 21% | N/A |
| Q2 2023 | 22% | N/A |
NAMI's operating margin was −10% last quarter, down 26 points from the same quarter a year ago.
META Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -110% |
| Q2 2026 | $1.7B | -81% |
| Q1 2026 | $13.2B | +19% |
| Q4 2025 | $14.8B | +9.3% |
| Q3 2025 | $11.2B | -32% |
| Q2 2025 | $9B | -19% |
| Q1 2025 | $11.1B | -14% |
| Q4 2024 | $13.6B | +16% |
META usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $28.6B over the past year.
NAMI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$413.5K | -137% |
| Q4 2025 | -$4.9M | -810% |
| Q2 2025 | $1.1M | -63% |
| Q4 2024 | $693K | -76% |
| Q2 2024 | $3M | -46% |
NAMI and META do not have enough comparable growth data to identify a winner.
META Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.0x | Very low |
| Q4 2024 | -0.2x | Net Cash |
META's net debt is less than a year of its operating earnings (EBITDA).
NAMI Net Leverage
NAMI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
META Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 33.7 | Neutral |
META's weekly RSI is 48 (neutral) and its Stochastic is 34 (neutral).
NAMI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.0 | Neutral |
| Stochastic | 3.9 | Oversold |
NAMI's weekly RSI is 31 (neutral) and its Stochastic is 4 (oversold).
META PE vs Communication Services Sector
| Metric | META | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 16x | 29% above |
| PE % | 18 | 26 | 8 pts below |
META is trading at 21x earnings, a 29% premium to the Communication Services sector's median of 16x.
NAMI PE vs Communication Services Sector
NAMI has no meaningful PE right now: it lost money over the past year.
META Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $674.9 | 7.6% below |
| 20 week MA | $634.5 | 1.7% below |
| 50 week MA | $630.8 | 1.1% below |
| 100 week MA | $647.8 | 3.7% below |
| 200 week MA | $517.5 | 21% above |
META has stronger trend alignment. META is above 1 of 5 weekly averages versus NAMI above 0 of 4.
NAMI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.86 | 13% below |
| 20 week MA | $2.50 | 35% below |
| 50 week MA | $8.83 | 82% below |
| 100 week MA | $30.2 | 95% below |
NAMI is in a downtrend: it's below all four of its weekly moving averages, and 95% below its 100-week average.
META Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $208.1 | $267.4 | +28% |
| 2021 | $267.4 | $335.2 | +25% |
| 2022 | $335.2 | $118.0 | -65% |
| 2023 | $118.0 | $354.0 | +200% |
| 2024 | $354.0 | $599.8 | +69% |
| 2025 | $599.8 | $663.3 | +11% |
| 2026 YTD | $663.3 | $623.6 | -6% |
META has the edge over NAMI on returns for 2026, with the stronger performance.
NAMI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $111.0 | $104.5 | -5.9% |
| 2025 | $104.5 | $18.4 | -82% |
| 2026 YTD | $18.4 | $1.62 | -91% |
NAMI has finished every year since 2024 lower, and it's down 91% so far in 2026.